Interim analysis of a phase 3 trial in 413 patients with PD-L1-positive advanced NSCLC: first-line sac-TMT plus pembrolizumab lengthened median progression-free survival vs pembrolizumab alone (not reached vs 5·7 months; HR 0·35). Grade ≥3 adverse events 55% vs 31%.
RCTn = 413
Xiong et al. Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial